Vanguard Group Inc. Has $16.50 Million Holdings in Rockwell Medical, Inc. (RMTI)
Vanguard Group Inc. raised its position in Rockwell Medical, Inc. (NASDAQ:RMTI) by 4.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,080,843 shares of the company’s stock after acquiring an additional 90,786 shares during the quarter. Vanguard Group Inc. owned approximately 4.00% of Rockwell Medical worth $16,501,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its position in shares of Rockwell Medical by 1,725.7% in the second quarter. PNC Financial Services Group Inc. now owns 15,245 shares of the company’s stock valued at $121,000 after acquiring an additional 14,410 shares during the period. KCG Holdings Inc. purchased a new position in shares of Rockwell Medical in the first quarter valued at about $111,000. UBS Asset Management Americas Inc. increased its position in shares of Rockwell Medical by 38.3% in the second quarter. UBS Asset Management Americas Inc. now owns 19,843 shares of the company’s stock valued at $157,000 after acquiring an additional 5,500 shares during the period. Private Advisor Group LLC purchased a new position in shares of Rockwell Medical in the second quarter valued at about $182,000. Finally, Cutter & CO Brokerage Inc. increased its position in shares of Rockwell Medical by 6.3% in the second quarter. Cutter & CO Brokerage Inc. now owns 25,325 shares of the company’s stock valued at $201,000 after acquiring an additional 1,500 shares during the period. Hedge funds and other institutional investors own 21.73% of the company’s stock.
Shares of Rockwell Medical, Inc. (RMTI) opened at $6.39 on Friday. Rockwell Medical, Inc. has a 52 week low of $5.06 and a 52 week high of $8.98.
Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Wednesday, November 8th. The company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $14.63 million for the quarter, compared to analyst estimates of $13.33 million. Rockwell Medical had a negative net margin of 34.57% and a negative return on equity of 47.93%. The company’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.09) EPS. equities analysts expect that Rockwell Medical, Inc. will post -0.44 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Vanguard Group Inc. Has $16.50 Million Holdings in Rockwell Medical, Inc. (RMTI)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/18/vanguard-group-inc-has-16-50-million-holdings-in-rockwell-medical-inc-rmti.html.
A number of equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research report on Wednesday, October 25th. BidaskClub lowered shares of Rockwell Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Ifs Securities began coverage on shares of Rockwell Medical in a research note on Monday, August 14th. They set a “strong-buy” rating and a $11.00 target price on the stock.
Rockwell Medical Profile
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Stock Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related stocks with our FREE daily email newsletter.